These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Donnelly A; Blagg BS Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631 [TBL] [Abstract][Full Text] [Related]
3. A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas. Sanchez JN; Subramanian C; Chanda M; Shanguan G; Zhang N; Wang T; Timmermann BN; Blagg BSJ; Cohen MS Melanoma Res; 2021 Jun; 31(3):197-207. PubMed ID: 33904516 [TBL] [Abstract][Full Text] [Related]
4. From Bacteria to Cancer: A Benzothiazole-Based DNA Gyrase B Inhibitor Redesigned for Hsp90 C-Terminal Inhibition. Pugh KW; Zhang Z; Wang J; Xu X; Munthali V; Zuo A; Blagg BSJ ACS Med Chem Lett; 2020 Aug; 11(8):1535-1538. PubMed ID: 32832020 [TBL] [Abstract][Full Text] [Related]
5. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors. Garg G; Forsberg LK; Zhao H; Blagg BSJ Chemistry; 2017 Nov; 23(65):16574-16585. PubMed ID: 28940589 [TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N-terminal Inhibitors Without Induction of Heat Shock Response. Liu P; Chen X; Zhu J; Li B; Chen Z; Wang G; Sun H; Xu Z; Zhao Z; Zhou C; Xie C; Lou L; Zhu W ChemistryOpen; 2019 Mar; 8(3):344-353. PubMed ID: 30976475 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Smyth T; Paraiso KHT; Hearn K; Rodriguez-Lopez AM; Munck JM; Haarberg HE; Sondak VK; Thompson NT; Azab M; Lyons JF; Smalley KSM; Wallis NG Mol Cancer Ther; 2014 Dec; 13(12):2793-2804. PubMed ID: 25349308 [TBL] [Abstract][Full Text] [Related]
8. Hsp90 inhibitors identified from a library of novobiocin analogues. Yu XM; Shen G; Neckers L; Blake H; Holzbeierlein J; Cronk B; Blagg BS J Am Chem Soc; 2005 Sep; 127(37):12778-9. PubMed ID: 16159253 [TBL] [Abstract][Full Text] [Related]
9. Structure-Activity Relationships of Benzothiazole-Based Hsp90 C-Terminal-Domain Inhibitors. Dernovšek J; Zajec Ž; Durcik M; Mašič LP; Gobec M; Zidar N; Tomašič T Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452244 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors. Garg G; Zhao H; Blagg BS Bioorg Med Chem; 2017 Jan; 25(2):451-457. PubMed ID: 27914946 [TBL] [Abstract][Full Text] [Related]
11. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide. Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977 [TBL] [Abstract][Full Text] [Related]
12. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model. Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571 [TBL] [Abstract][Full Text] [Related]
13. A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells. Samadi AK; Zhang X; Mukerji R; Donnelly AC; Blagg BS; Cohen MS Cancer Lett; 2011 Dec; 312(2):158-67. PubMed ID: 21924824 [TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Matthews SB; Vielhauer GA; Manthe CA; Chaguturu VK; Szabla K; Matts RL; Donnelly AC; Blagg BS; Holzbeierlein JM Prostate; 2010 Jan; 70(1):27-36. PubMed ID: 19739131 [TBL] [Abstract][Full Text] [Related]
15. Stimulation of heat shock protein 90 chaperone function through binding of a novobiocin analog KU-32. Chatterjee BK; Jayaraj A; Kumar V; Blagg B; Davis RE; Jayaram B; Deep S; Chaudhuri TK J Biol Chem; 2019 Apr; 294(16):6450-6467. PubMed ID: 30792306 [TBL] [Abstract][Full Text] [Related]
16. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells. Liu W; Vielhauer GA; Holzbeierlein JM; Zhao H; Ghosh S; Brown D; Lee E; Blagg BS Mol Pharmacol; 2015 Jul; 88(1):121-30. PubMed ID: 25939977 [TBL] [Abstract][Full Text] [Related]
17. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Shelton SN; Shawgo ME; Matthews SB; Lu Y; Donnelly AC; Szabla K; Tanol M; Vielhauer GA; Rajewski RA; Matts RL; Blagg BS; Robertson JD Mol Pharmacol; 2009 Dec; 76(6):1314-22. PubMed ID: 19741006 [TBL] [Abstract][Full Text] [Related]
18. Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues. Peterson LB; Blagg BS Bioorg Med Chem Lett; 2010 Jul; 20(13):3957-60. PubMed ID: 20570149 [TBL] [Abstract][Full Text] [Related]
20. HEAT SHOCK PROTEIN 90C is a bona fide Hsp90 that interacts with plastidic HSP70B in Chlamydomonas reinhardtii. Willmund F; Schroda M Plant Physiol; 2005 Aug; 138(4):2310-22. PubMed ID: 15995001 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]